发明名称 IRE-1alpha Inhibitors
摘要 Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
申请公布号 US2016168116(A1) 申请公布日期 2016.06.16
申请号 US201514969837 申请日期 2015.12.15
申请人 MannKind Corporation 发明人 Patterson John B.;Lonergan David G.;Flynn Gary A.;Zeng Qingpeng;Pallai Peter V.
分类号 C07D333/58;C07D333/22;C07D239/26;C07D321/10;C07C65/30;C07C205/44;C07D317/54;C07D231/12;C07D307/80;C07D213/69;C07D319/18;C07D261/08;C07D213/48;C07C47/565;C07D215/14;C07D217/16;C07D295/192;C07C235/84;C07C317/24;C07D295/15;C07D241/18;C07C47/575 主分类号 C07D333/58
代理机构 代理人
主权项 1. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of structural formula (A): wherein: R1 is hydrogen, halogen, or a 5- or 6-membered heterocyclic containing one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur;R2 is hydrogen,phenyl, or a 5- or 6-membered heterocyclic containing 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the heterocyclic is optionally benzofused and wherein the heterocyclic is optionally substituted by 1, 2, or 3 substituents independently selected fromC1-C3 linear or branched alkyl,C1-C3 phenylalkyl, C1-C3 alkoxyphenylalkyl, R3 is hydrogen, halogen, —NO2, C1-C3 linear or branched alkoxy, C1-C3 linear or branched hydroxyl alkyl,and Q is a five- or six-membered heterocycle.
地址 Valencia CA US